For Teens, Protection Against SARS-CoV-2 Highest for Hybrid Immunity
By Elana Gotkine HealthDay Reporter
TUESDAY, Nov. 14, 2023 -- Protection against severe acute respiratory syndrome coronavirus 2 (SAR-CoV-2) infection is highest for middle and high school students with hybrid immunity from previous infection and recent COVID-19 vaccination with a third dose, according to a study published online Nov. 14 in Pediatrics.
Olivia M. Almendares, M.S.P.H., from the COVID-19 Response Team at the U.S. Centers for Disease Control and Prevention in Atlanta, and colleagues used data from 17,910 Utah middle and high school students participating in schoolwide antigen testing in January 2022 to estimate the protection of previous SARS-CoV-2 infection and COVID-19 vaccination against SARS-CoV-2 infection.
The researchers found that 16.7 percent of the students had documented previous SARS-CoV-2 infection; 55.6 percent had received two vaccine doses and 8.6 percent of those aged 16 to 19 years had received three doses, with 211 and 21 median days since the second and third doses, respectively. For students aged 12 to 15 and 16 to 19 years, protection from previous infection alone was 35.9 and 23.8 percent, respectively. For two-dose hybrid immunity (previous SARS-CoV-2 infection plus vaccination) with <180 days since the second dose, protection was 58.7 and 54.7 percent for students age 12 to 15 and 16 to 19 years, respectively. The highest protection was seen for students with three-dose hybrid immunity (70.0 percent), although the confidence intervals overlapped with two-dose vaccination.
"These real-world, programmatic data from school-based testing were useful to reveal the relative effectiveness of past infection and/or vaccination in preventing infections in child and adolescent populations," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2023-11-15 01:13
Read more
- Medicaid Covers GLP-1 Meds for Obesity in Just 13 States
- IDSA: EHR Order Set Reduces Antibiotic Duration in Children With AOM
- Protega Pharmaceuticals Receives FDA Approval for RoxyBond (oxycodone hydrochloride) Immediate-Release 10 mg Tablet with Abuse-Deterrent Technology for Management of Pain
- Election Fears Are Keeping Americans Awake at Night, Survey Shows
- Phase 2 study demonstrates the first successful clinical application of antifibrotic therapy for breast cancer
- Protracted Radiation Exposure Linked to Hematologic Cancer Mortality
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions